Related Experiment Video
Updated: Jun 10, 2026
03:08
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
From NPC therapeutic target identification to potential treatment strategy
Ming-Ying Lan1, Chi-Long Chen, Kuan-Ting Lin
1Department of Otolaryngology, Taichung Veterans General Hospital, Taichung, Taiwan.
Molecular Cancer Therapeutics
|August 19, 2010
Summary
This study identifies key genes involved in nasopharyngeal carcinoma (NPC) development. By analyzing gene networks, researchers prioritized potential drug targets, offering a new approach for NPC treatment strategies.
Area of Science:
- Oncology
- Bioinformatics
- Systems Biology
Background:
- Nasopharyngeal carcinoma (NPC) is prevalent in Southern Asia, with numerous identified differentially expressed genes.
- Prioritizing therapeutic targets and drugs from extensive gene lists for NPC remains a significant challenge.
Purpose of the Study:
- To develop a computational pipeline for identifying key regulatory genes and potential therapeutic drugs for nasopharyngeal carcinoma.
- To prioritize therapeutic targets and drugs from unsorted gene lists using network analysis.
Main Methods:
- Collected and analyzed upregulated and downregulated genes from published data.
- Constructed protein-protein interaction networks to identify clique-based hubs and bottleneck genes.
- Integrated network analysis with pathway analysis and functional profiling to generate a final gene signature.
- Queried the Connectivity Map with gene signatures to identify potential drugs.
Main Results:
- Identified 24 upregulated and 6 downregulated bottleneck genes crucial for NPC carcinogenesis.
- Generated a final gene signature comprising 38 upregulated and 10 downregulated genes.
- Successfully identified potential drugs with cytotoxicity against NPC cancer cells using the developed pipeline.
Conclusions:
- The in silico approach effectively prioritizes therapeutic targets and identifies potential drugs for nasopharyngeal carcinoma.
- This method offers a valuable strategy for various cancer research, facilitating target identification and drug discovery.
Related Concept Videos
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...